Overall Pipeline Strategy: We are initially focused ion topical AMR infections since (a)  the size of the market is so large and (b) there are virtually no other affordable solutions, either on the market or under development, to treat or prevent such infections at a reasonable cost.  However, over time, in addition to our eczema and acne treatments, we will look to in-license later stage biological dermatological treatments for some underserved indications including for the following problems: additional AMR topical solutions, oncodermatology, actinic keratosis, and/or psoriasis. As we expand we will become one of the leading skin sciences companies in China.

Leveraging the Pipeline - Creating Revenue/Cash Flow from Out-licensing Platform Technologies: The Phagelux pipeline has considerable value, either for :

ROW – Skin Care Products:  All non-China rights will be open for out-licensing.  

Non-Core Best in Class Assets: All uses of lysin products for internal uses, whether in China or outside, will be available for out-license. Of particular value is Cly0, which is a Best-in-Class staph lysin. The second in class was out-licensed post-Phase I for $667M USD  (milestones plus low teens royalty). Sustained release for use on implants could also have significant value. 

Mark Engel

CEO

Previously founded 4 successful life sciences companies

Dr. Nancy Tawil 

Chief Scientific Officer

Ph.D in Biomedical Engineering and Phage Expert

Dr. Assaf Raz

Lab Manager - Wuhan

Ph.D in Biology and Leading Global Lysin Expert

Sandy Li

Quality Manager

M.S. in Chemistry. Experienced in GMP

drug production

Dr. Iness Hammami

Vice-President, Research

Ph.D in Chemical Engineering.

10 years of experience in biopharmaceutical engineering

Key Advisors

Clinical Advisors:

Dr. Tan Linshi, Chairman, dMed (www.dmedglobal.com)

Dr. Chen Wei, Executive Director of Regulatory Affairs,  WuXi AppTec Regulatory Services (www.wuxiapptec.com)

Skin Care Commercial Advisors:

Robert Braithwaite, Founder and Chairman of Luqa Pharma

Banking Advisor - Global:

Dave Sebow, Head of Global Healthcare, Silicon Valley Bank

China Topical AMR Infections Advisors:

Dr. Zhu Tong Yu, President of Zhongshan Hospital 

China Burn Infection Advisor:

Dr. Huang Guangtao, expert on burns and phages (trained under Dr. Hu Fuquan at 3rd Military Medical University, the leading burn hospital in China)

IPO Advisors:

Michael Chui, Head of Healthcare Asia, Goldman Sachs

All existing major investors

Phagelux is a Cayman platform company, focused on China first, that utilizes phages, lysins, and novel delivery systems to create First in Class treatments for large unmet or under met skin conditions. Phagelux Targets are effectively preventing and treating AMR resistant topical infections, and difficult to treat Eczema and Acne cases. It has R&D centers in Montreal, Canada and Wuhan, China. The former is focused on bacteriophage products while the latter develops lysin products.

Phagelux has 2 Highly Novel  Platforms: Sustained Released Treatments (Phage and   Bioengineering–First IND approved ; Lead Product IND Expect Q1 2021) and Engineered lysins (Enhanced Phage–IND by mid of 2021).

Many Patents – all Include China: Phagelux has a cumulative of 26 patents filed, including 8 that have been approved. All patents filed in all key markets including China.

Know How: Phagelux scientists have a very large amount of know how.

Major Shareholders include WuXi AppTec (25,000 plus scientists worldwide), the Management Team, Fosun Pharma ($80B market cap), Oriza (Yuan He)(leading Chinese VC) and BioTrack (leading Chinese VC).

IPO in Hong Kong or New Shanghai Exchange: Phagelux plans to list in Hong Kong or Shanghai before 2024. This will primarily be based on the current pipeline of the company. But Phagelux is already targeting some product acquisitions for the China market. 

Jan.16, 2020  Phagelux CEO Mark Engel interviewed at JP Morgan Conference. Phagelux looks to raise $20M USD plus, primarily to fund clinical trials. Phagelux clinical programs will uniquely address very large antibiotic resistant pathogen targets.